Navigation Links
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:11/18/2013

THOUSAND OAKS, Calif., Nov. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). Results will be presented today during an oral session at the 2013 Society for Melanoma Research (SMR) Congress, in Philadelphia.  

At a predefined interim analysis of this Phase 3 study, median OS was 23.3 months in the talimogene laherparepvec arm over 19.0 months in the GM-CSF arm (HR = 0.79, 95 percent CI 0.61-1.02; p=0.0746). Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease (HR = 0.56, 95 percent CI, 0.38-0.81) or who received talimogene laherparepvec as first-line treatment (HR = 0.49, 95 percent CI, 0.33-0.74), each comprising approximately 50 percent of the study population.

"The interim overall survival subset results complement the durable response data we reported earlier this year and these endpoints appear to correlate with each other in terms of where the most benefit is being seen in this trial," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We look forward to the mature overall survival data expected in the first half of next year."

The most frequently observed adverse events were fatigue, chills and pyrexia. The most common serious adverse events include disease progression in both arms, and cellulitis and pyrexia in the talimogene laherparepvec arm. Serious adverse events occurred in 26 percent of talimogene laherparepvec patients and 13 percent of GM-CSF patients. Immune-mediated events were reported infrequently. 
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 In keeping with the holiday ... bevy of last-minute Thanksgiving savings. The company is offering ... all product lines this holiday weekend as well as ... Friday, and Cyber Monday are right around the corner, ... both loyal customers and those looking to explore their ...
(Date:11/26/2014)... 26, 2014 The ETC (Emerging ... technology innovation centers, announced today that applications for ... December 1st. “Do you have a big idea?,” ... want to know about it. AccelerateBaltimore helps you ... product in just 13 weeks.” Interested game ...
(Date:11/26/2014)... 25, 2014 Continuing its award-winning streak, ... three prestigious MarCom Awards for outstanding creative achievement by ... Platinum MarCom Award, the organization’s top honor, in the ... Louis held in April of this year. The event ... attendees. Additionally, Nerium was awarded a Gold MarCom Award ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 CURE™ ... recognition reception on December 5, 2014, in San Francisco ... The MPN Heroes event will honor clinicians, caregivers, and ... of myeloproliferative neoplasms (MPNs). , Special guest speaker ... his family's cancer journey at the reception. Over ...
Breaking Biology Technology:DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Cystinosis Foundation Ireland to Host Event June 27-28, ... Corp. ("Raptor" or the "Company") (OTC Bulletin Board:,RPTP), ... clinical,division, will present at the Cystinosis Foundation Ireland,s ... 2008 at the,Hilton Hotel, Dublin City, Charlemont Place, ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... services, today announced Health Canada -- Medical,Device ... of the ATS,Open Pivot(R) AP360(TM) Mechanical Heart ... The ATS AP360 heart valve maximizes ...
Cached Biology Technology:Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve 2
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/5/2014)... diversity in their ability to identify scents and odors. ... their perceptual evaluation of odors, with women outperforming men ... Sex differences in olfactory detection may play a role ... one,s perception of smell, which is naturally linked to ... been suggested to be cognitive or emotional, rather than ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... gene that contributes to insulin resistance appears to prevent ... researchers say. Cardiovascular disease is the biggest health ... trying to understand why have knocked out protein tyrosine ... get diabetes. "Even before you have really bad ...
... to move swiftly to pass economic recovery legislation ... including the National Science Foundation (NSF), the Department ... and Space Administration (NASA), and National Institute of ... of the American Recovery and Reinvestment Act included ...
... National Institute of Standards and Technology (NIST) has ... be an important quality assurance tool for measuring ... in dietary supplements. The new Standard Reference Material ... collaboration with the Office of Dietary Supplements (ODS) ...
Cached Biology News:Decreasing insulin resistance prevents obesity-related cardiovascular damage 2Decreasing insulin resistance prevents obesity-related cardiovascular damage 3Basic research critical to America's economic recovery 2New reference material can improve testing of multivitamin tablets 2
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Biology Products: